What Biotech Startup Funding Requires That Medtech Founders Often Miss

Published

September 29, 2026

Table of contents

Biotech startup funding requires founders to understand a market with structurally less competitive tension than medtech, and most medtech founders crossing into biotech miss that difference until they're already in a room with one buyer and no leverage.

Key Takeaways

85% of biotech deals involve only one buyer, which means most biotech founders are negotiating with zero competitive tension whether they realize it or not.
Clinical validation is not adoption, FDA clearance is not demand, and biotech founders who confuse the three walk into funding conversations with the wrong pitch.
Santé Ventures' Dennis McWilliams sees first-time founders assume they'll own 20 to 30 percent of the company at exit, when early-round dilution rarely leaves that much on the table.
Biotech needs a healthy M&A market to exist at all, because trial costs run into the billions, a capital reality medtech founders crossing over often underestimate.
Founders who spend years building a credible alternative to selling walk into funding and exit conversations with leverage. The ones who wait arrive with none.

Why Most Biotech Deals Happen With Zero Competitive Tension

A hallway of closed doors except one open at the end, showing limited buyer options in biotech deals

The single fact that reshapes how a founder should approach biotech startup funding is how concentrated the buyer pool is. Most founders don't learn this until they're already negotiating.

I covered this on an episode breaking down $17 billion in medtech exits:

"85% of all biotech deals involve only one buyer. One buyer means no competitive tension.

Clinical validation is not adoption. FDA clearance is not demand. And innovation alone does not create a category."

A founder who assumes a strong clinical result will attract competing bidders is planning for a negotiation that statistically almost never happens. One buyer means that buyer sets the terms, not the founder.

The remedy isn't clinical. It's structural: build enough narrative and market credibility before the funding or exit conversation starts that a single buyer has to compete against the option of you not needing them at all.

Why Clinical Validation Gets Mistaken for Market Traction

A single domino tipping alone, separated from a still row, showing clinical validation without repeatable traction

Biotech startup funding conversations run on a specific kind of proof, and it isn't the proof most technical founders default to presenting. FDA clearance and strong trial data answer a different question than the one investors are asking.

I made the same distinction on an episode about how market engineering helps medtech startups raise capital:

Traction isn't revenue, a product launch, or a clinical milestone. Traction is repeatable, measurable demand. Revenue can be episodic, and one or two deals doesn't mean a company has repeatability, predictability, or scalability.

A founder walking into a funding round with clinical results and a handful of early sales often can't understand why investors still call it "promising" instead of fundable. The data proves the product works. It doesn't prove a market wants it repeatably.

That gap between clinical proof and demand proof is exactly where biotech funding conversations stall, and it's rarely framed to founders as a market problem instead of a fundraising problem.

Why Founders Misjudge How Much Equity They Keep

A pastry cut into progressively thinner slices, showing equity diluted across funding rounds

Biotech startup funding runs on a dilution curve most first-time founders have never modeled honestly. The ownership math looks very different by the time an exit happens.

I interviewed Dennis McWilliams of Santé Ventures on an episode about VC discipline in early medtech strategy. He described the mentor who talked him through this exact question early in his own career:

"Do you want to own a small piece of the donut, or a big piece of the donut hole? At the end of the day, if you need capital for what you're doing, you're going to have to raise it at market terms."

McWilliams points to founders who raised big rounds at inflated valuations in 2021: in almost every case, the company got fully recapped and the common stock was wiped out.

The mistake isn't raising money. It's not modeling what later rounds do to ownership.

Founders who understand this going in negotiate differently in the earliest rounds, because they know exactly what those terms compound into three or four rounds later.

Why Medtech Capital Leverage Doesn't Transfer to Biotech's Capital Needs

Founders moving between medtech and biotech often carry medtech's capital assumptions into a biotech fundraising conversation, and the assumptions don't transfer. The two industries run on different cost structures entirely.

I covered this distinction on an episode reviewing recent medtech M&A activity:

"Biotech needs a healthy M&A market because it costs a lot of money to go through those different phases, billions and billions of dollars.

In medtech, it doesn't cost a lot of money to go through clinical trials, but it does cost a lot to develop and distribute."

That difference changes what a biotech funding pitch needs to prove. A medtech founder pitches distribution and adoption economics. A biotech founder has to account for capital-intensive trial phases that can run for years before any revenue exists at all.

A founder who pitches biotech investors with a medtech-style adoption narrative is answering a question those investors aren't asking, because the capital math behind the two industries barely resembles each other.

What This Means for Medtech Founders

In my experience working with medtech founders, the ones moving into biotech funding for the first time consistently underestimate how much leverage depends on narrative built years in advance, not on the strength of a single trial result.

The founders who get this right start building that leverage early. They understand the buyer pool is thin, they define traction as repeatable demand rather than a clinical milestone, and they model dilution honestly instead of assuming they'll keep a founder-friendly share at exit.

They also stop pitching biotech investors with medtech logic. The capital structures, the trial costs, and the M&A dynamics are different enough that reusing a medtech pitch reads as a founder who hasn't done the homework.

Biotech startup funding rewards founders who show up already understanding these mechanics. It punishes the ones who learn them mid-negotiation, with a single buyer already at the table.

Frequently Asked Questions

Why Do Most Biotech Deals Have Only One Buyer?

Biotech's high capital costs concentrate the buyer pool to strategics with the balance sheet to absorb billion-dollar trial phases.

That concentration means most founders negotiate exits and funding rounds without the competitive tension a wider buyer pool would create. A founder who spends years building a credible alternative to selling walks into that negotiation with leverage instead of none.

What Do Investors Mean by Traction in Biotech Funding?

Investors define traction as repeatable, measurable demand, not a single clinical milestone or an early sale. A founder with strong trial data but only one or two deals hasn't demonstrated traction yet, even if the product clearly works.

Revenue that's episodic doesn't prove a market wants the product repeatably, and that gap between clinical proof and demand proof is where biotech funding conversations tend to stall.

How Much Equity Do Biotech Founders Typically Keep After Multiple Funding Rounds?

Often far less than the 20 to 30 percent many first-time founders assume.

Founders who raised big rounds at inflated valuations in 2021 saw some of the starkest examples: in almost every case, the company was fully recapped and the common stock was wiped out.

Raising capital always means giving up ownership at market terms, so founders who model that dilution honestly before their first round fare better than ones who don't.

Where to Go From Here

If you're doing this yourself. Read the medtech commercialization strategy breakdown to see how narrative and category work build the leverage a thin buyer pool otherwise takes away.

If you want it engineered with you. MarketCraft takes on a small number of medtech teams each quarter, starting with The Market Engineering Audit. For founders about to raise in a market with one likely buyer, the audit maps where leverage is missing before the term sheet does.

Listen to the Full Conversations

Subscribe wherever you listen to podcasts.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry.

He works with medtech founders and commercial leaders on market engineering, commercialisation strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.